🔴 Just presented at #ESMO2026: DASL-HiCaP
Adding darolutamide to ADT + locoregional RT significantly improved metastasis-free survival in very high-risk localised or biochemically persistent/recurrent prostate cancer in the DASL-HiCaP trial.
At 4 years:
🔹 MFS: 95% vs 88% (HR 0.42)
🔹 PSA-PFS: 91% vs 83% (HR 0.47)
🔹 PCSS: 99% vs 99% (HR 0.58)
🔹 OS: 97% vs 95% (HR 0.88)
Grade ≥3 adverse events occurred in 43% with darolutamide vs 36% with placebo.
Follow-up is ongoing to assess longer-term outcomes, including OS.
#ESMO26 #ProstateCancer #Darolutamide #DASLHiCaP
33 浏览 · 0 赞 · 0 转发 · 0 回复
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgPerioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgDarolutamide with androgen deprivation therapy (ADT) and definitive or salvage locoregional radiation therapy (RT) for localised, very high-risk prostate cancer: Interim analysis of an international, placebo-controlled, randomised phase 3 t
https://esmocongress.esmo.org来源：Mirrors of Medicine · x.com